다계통 위축증(MSA) 치료제 파이프라인 분석(2026년) : 2분기 임사이트 및 임상시험

Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by autonomic dysfunction, parkinsonian symptoms, cerebellar impairment, and widespread neurological deterioration. Despite significant advances in neuroscience research, MSA remains an area of substantial unmet medical need due to the absence of widely available disease-modifying treatments. Current therapeutic approaches are largely focused on symptomatic management, creating strong demand for innovative therapies capable of slowing or preventing disease progression.

Drug pipeline analysis has become increasingly important for pharmaceutical companies, biotechnology firms, investors, healthcare consultants, and research organizations seeking to evaluate future market opportunities and competitive positioning. Pipeline intelligence provides insights into clinical development trends, therapeutic targets, molecule types, regulatory pathways, strategic collaborations, and commercialization prospects. Growing scientific understanding of disease mechanisms, particularly alpha-synuclein aggregation and neurodegeneration, is supporting the development of a diverse range of investigational therapies and expanding the overall MSA pipeline landscape.

Market Drivers

Increasing Focus on Disease-Modifying Therapies

One of the primary growth drivers is the industry's transition from symptomatic treatment approaches toward therapies designed to modify the underlying disease process. Researchers are increasingly targeting alpha-synuclein accumulation, neuroinflammation, mitochondrial dysfunction, and neuronal degeneration.

The pursuit of disease-modifying interventions has expanded research activity across multiple therapeutic modalities, creating a more dynamic and competitive development environment.

Expansion of Orphan Drug Development

MSA qualifies as a rare disease in major pharmaceutical markets, allowing developers to benefit from orphan drug incentives such as regulatory support, market exclusivity, fee reductions, and accelerated development pathways.

These incentives are encouraging greater participation from biotechnology and pharmaceutical companies and are helping to strengthen the overall pipeline of investigational therapies.

Growing Clinical Trial Activity

Clinical development activity continues to increase as more companies advance promising candidates into human studies. Early-stage and mid-stage clinical programs are becoming increasingly important as sponsors evaluate safety, efficacy, biomarkers, and disease progression endpoints.

Growing clinical trial activity is generating valuable pipeline intelligence and supporting strategic investment decisions throughout the MSA ecosystem.

Advances in Disease Biology Research

Improved understanding of MSA pathogenesis has accelerated the identification of novel therapeutic targets. Research into alpha-synuclein pathology, protein aggregation, neuroprotective pathways, inflammatory mechanisms, and genetic regulation is creating new opportunities for innovative drug development.

These scientific advances are supporting a broader range of development programs and increasing the probability of future therapeutic breakthroughs.

Market Restraints

Limited Patient Population

As a rare disease, MSA affects a relatively small number of patients worldwide. The limited patient pool creates challenges for clinical trial recruitment, epidemiological studies, and commercial market sizing.

Recruitment difficulties may increase development timelines and costs, slowing pipeline progression.

High Clinical Development Risk

Neurodegenerative disease drug development remains associated with significant scientific uncertainty and elevated failure rates. Demonstrating meaningful clinical benefit in MSA can be challenging due to disease complexity and progression variability.

Many promising therapies may encounter difficulties during clinical evaluation, creating substantial investment risk.

Lack of Validated Biomarkers

The absence of widely accepted biomarkers and surrogate endpoints continues to complicate therapeutic assessment. Developers often rely on clinical outcome measures that require lengthy observation periods.

These limitations can increase development complexity and affect regulatory timelines.

Technology and Segment Insights

The global multiple system atrophy drug pipeline analysis market can be segmented by development stage, molecule type, mechanism of action, therapy platform, end user, and geography.

By development stage, the market includes discovery, preclinical, Phase I, Phase I/II, Phase II, Phase II/III, Phase III, and registration-stage programs. Discovery and preclinical programs account for a substantial share of pipeline activity as researchers continue identifying novel therapeutic targets. Phase II remains one of the most strategically significant segments because proof-of-concept data generated at this stage often influences future investment and partnership decisions.

By molecule type, the market includes small molecules, monoclonal antibodies, antisense oligonucleotides, gene therapies, cell therapies, peptides, and other advanced therapeutic modalities. Small molecules currently represent a significant portion of the pipeline due to established development pathways and scalable manufacturing. However, biologics, RNA-based therapies, and gene therapies are gaining momentum as developers pursue highly targeted treatment strategies.

By mechanism of action, the market includes alpha-synuclein targeting therapies, neuroprotective therapies, anti-inflammatory agents, protein aggregation inhibitors, gene-based approaches, cell-based therapies, and other emerging mechanisms. Alpha-synuclein-targeted therapies represent one of the most active development areas because protein aggregation is widely considered a central driver of disease progression.

By therapy platform, the market encompasses biologics, molecular therapeutics, RNA therapeutics, regenerative medicine, precision medicine approaches, and advanced neurological interventions. Emerging technologies are increasingly focused on addressing the root causes of disease rather than managing symptoms alone.

By end user, the market serves pharmaceutical companies, biotechnology firms, contract research organizations, academic institutions, investors, healthcare consulting firms, and competitive intelligence providers. Pharmaceutical and biotechnology companies account for a substantial share due to ongoing portfolio assessment and strategic planning activities.

Several notable investigational candidates are advancing through development, including Amlenetug, ATH434, AB-1005, Foralumab, KM-819, ION464, PMN442, and other emerging therapies targeting diverse disease pathways. The pipeline currently includes more than 20 companies and over 20 investigational products across multiple stages of development.

Technological innovation is playing an increasingly important role in pipeline development. Artificial intelligence, biomarker discovery platforms, advanced neuroimaging technologies, genomic research, and precision medicine tools are improving target identification, patient stratification, and clinical trial design. These capabilities are enhancing development efficiency and supporting more sophisticated therapeutic approaches.

Geographically, North America represents the leading market due to strong neuroscience research infrastructure, significant rare disease funding, active clinical development programs, and favorable orphan drug policies. Europe remains an important market supported by collaborative research initiatives and regulatory incentives. Asia-Pacific is expected to experience growing activity as healthcare investments increase and neurological research capabilities expand.

Competitive and Strategic Outlook

The competitive landscape is becoming increasingly dynamic as biotechnology firms and pharmaceutical companies pursue differentiated strategies for disease modification. Companies are investing heavily in alpha-synuclein-targeting therapies, neuroprotective agents, antisense technologies, gene therapies, and regenerative medicine approaches.

Strategic partnerships, licensing agreements, research collaborations, and co-development arrangements are becoming common as organizations seek to combine scientific expertise, clinical capabilities, and financial resources. Biotechnology companies continue to drive much of the innovation, while larger pharmaceutical organizations are increasingly participating through acquisitions, partnerships, and targeted investments.

Leading organizations active within the pipeline include companies such as Alterity Therapeutics, Biohaven, Lundbeck, AbbVie, Neurocrine Biosciences, Ionis Pharmaceuticals, AskBio, Ono Pharmaceutical, ProMIS Neurosciences, and several emerging biotechnology developers. Their collective efforts are expanding therapeutic diversity and strengthening the long-term outlook for MSA treatment innovation.

Conclusion

The global multiple system atrophy drug pipeline analysis market is poised for significant expansion through 2031, supported by increasing rare disease research, growing orphan drug incentives, advances in disease biology, and expanding clinical development activity. The pipeline is evolving toward mechanism-based therapies that target alpha-synuclein pathology, neurodegeneration, and disease progression. While challenges related to patient recruitment, biomarker development, and clinical risk remain, ongoing innovation across small molecules, biologics, antisense therapies, gene therapies, and regenerative medicine platforms is expected to create substantial opportunities for stakeholders throughout the MSA therapeutic ecosystem.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Key Findings
• 1.3 Pipeline Landscape Overview
• 1.4 Clinical Development Highlights
• 1.5 Key Emerging Therapies
• 1.6 Competitive Intelligence Snapshot
• 1.7 Future Outlook

2. Disease Overview

• 2.1 Introduction to Multiple System Atrophy (MSA)
• 2.2 Disease Pathophysiology
• 2.3 Disease Classification
  • 2.3.1 Multiple System Atrophy-Parkinsonian Type (MSA-P)
  • 2.3.2 Multiple System Atrophy-Cerebellar Type (MSA-C)
• 2.4 Disease Progression and Clinical Manifestations
• 2.5 Current Standard of Care
• 2.6 Unmet Medical Needs
• 2.7 Treatment Challenges

3. Treatment Landscape Analysis

• 3.1 Current Treatment Paradigm
• 3.2 Symptomatic Treatment Approaches
• 3.3 Pharmacological Therapies
• 3.4 Non-Pharmacological Management
• 3.5 Emerging Disease-Modifying Strategies
• 3.6 Treatment Algorithm Assessment
• 3.7 Future Treatment Trends

4. Pipeline Landscape Overview

• 4.1 Pipeline Snapshot by Development Stage
• 4.2 Pipeline Snapshot by Molecule Type
• 4.3 Pipeline Snapshot by Route of Administration
• 4.4 Pipeline Snapshot by Mechanism of Action
• 4.5 Pipeline Snapshot by Company Type
• 4.6 Dormant and Discontinued Programs
• 4.7 Promising Clinical Candidates
• 4.8 Future Innovation Areas

5. Clinical Trials Landscape Analysis

• 5.1 Clinical Trial Overview
• 5.2 Clinical Trials by Development Phase
  • 5.2.1 Phase I
  • 5.2.2 Phase I/II
  • 5.2.3 Phase II
  • 5.2.4 Phase II/III
  • 5.2.5 Phase III
• 5.3 Clinical Trials by Geography
• 5.4 Clinical Trials by Sponsor Type
• 5.5 Clinical Trials by Patient Population
• 5.6 Clinical Trial Endpoints Analysis
• 5.7 Recruitment and Enrollment Trends
• 5.8 Ongoing Clinical Trials Assessment
• 5.9 Completed Clinical Trials Assessment
• 5.10 Upcoming Clinical Milestones

6. Pipeline Segmentation Analysis

• 6.1 By Development Stage
  • 6.1.1 Discovery
  • 6.1.2 Preclinical
  • 6.1.3 Phase I
  • 6.1.4 Phase I/II
  • 6.1.5 Phase II
  • 6.1.6 Phase II/III
  • 6.1.7 Phase III
  • 6.1.8 Regulatory Stage
• 6.2 By Molecule Type
  • 6.2.1 Small Molecules
  • 6.2.2 Monoclonal Antibodies
  • 6.2.3 Antisense Oligonucleotides
  • 6.2.4 Gene Therapies
  • 6.2.5 Cell Therapies
  • 6.2.6 Peptides
  • 6.2.7 Other Novel Modalities
• 6.3 By Route of Administration
  • 6.3.1 Oral
  • 6.3.2 Intravenous
  • 6.3.3 Subcutaneous
  • 6.3.4 Intrathecal
  • 6.3.5 Intranasal
  • 6.3.6 Other Routes
• 6.4 By Mechanism of Action
  • 6.4.1 Alpha-Synuclein Targeting Therapies
  • 6.4.2 Neuroprotective Therapies
  • 6.4.3 Anti-Inflammatory Therapies
  • 6.4.4 Protein Aggregation Inhibitors
  • 6.4.5 Gene-Based Therapies
  • 6.4.6 Cell-Based Therapies
  • 6.4.7 Autonomic Dysfunction Therapies
  • 6.4.8 Other Novel Mechanisms

7. Competitive Intelligence Analysis

• 7.1 Competitive Landscape Overview
• 7.2 Company Benchmarking Analysis
• 7.3 Pipeline Strength Assessment
• 7.4 Clinical Stage Positioning
• 7.5 Innovation Index Assessment
• 7.6 Strategic Collaborations and Partnerships
• 7.7 Licensing and Acquisition Activity
• 7.8 Funding and Investment Trends
• 7.9 Emerging Innovators Analysis
• 7.10 Future Competitive Outlook

8. Clinical Trial Geography Analysis

• 8.1 North America
  • 8.1.1 Active Clinical Trials
  • 8.1.2 Research Infrastructure
  • 8.1.3 Regulatory Environment
  • 8.1.4 Investigator Network Analysis
  • 8.1.5 Future Growth Opportunities
• 8.2 Europe
  • 8.2.1 Active Clinical Trials
  • 8.2.2 Research Infrastructure
  • 8.2.3 Regulatory Environment
  • 8.2.4 Investigator Network Analysis
  • 8.2.5 Future Growth Opportunities
• 8.3 Asia-Pacific
  • 8.3.1 Active Clinical Trials
  • 8.3.2 Research Infrastructure
  • 8.3.3 Regulatory Environment
  • 8.3.4 Investigator Network Analysis
  • 8.3.5 Future Growth Opportunities
• 8.4 Latin America
  • 8.4.1 Active Clinical Trials
  • 8.4.2 Research Infrastructure
  • 8.4.3 Regulatory Environment
  • 8.4.4 Investigator Network Analysis
  • 8.4.5 Future Growth Opportunities
• 8.5 Middle East & Africa
  • 8.5.1 Active Clinical Trials
  • 8.5.2 Research Infrastructure
  • 8.5.3 Regulatory Environment
  • 8.5.4 Investigator Network Analysis
  • 8.5.5 Future Growth Opportunities

9. Key Countries Analysis

• 9.1 United States
  • 9.1.1 Active Clinical Trials
  • 9.1.2 Key Sponsors
  • 9.1.3 Research Infrastructure
  • 9.1.4 Regulatory Environment
  • 9.1.5 Funding Trends
  • 9.1.6 Investigator Activity
  • 9.1.7 Future Growth Opportunities
• 9.2 Canada
  • 9.2.1 Active Clinical Trials
  • 9.2.2 Key Sponsors
  • 9.2.3 Research Infrastructure
  • 9.2.4 Regulatory Environment
  • 9.2.5 Funding Trends
  • 9.2.6 Investigator Activity
  • 9.2.7 Future Growth Opportunities
• 9.3 Germany
  • 9.3.1 Active Clinical Trials
  • 9.3.2 Key Sponsors
  • 9.3.3 Research Infrastructure
  • 9.3.4 Regulatory Environment
  • 9.3.5 Funding Trends
  • 9.3.6 Investigator Activity
  • 9.3.7 Future Growth Opportunities
• 9.4 United Kingdom
  • 9.4.1 Active Clinical Trials
  • 9.4.2 Key Sponsors
  • 9.4.3 Research Infrastructure
  • 9.4.4 Regulatory Environment
  • 9.4.5 Funding Trends
  • 9.4.6 Investigator Activity
  • 9.4.7 Future Growth Opportunities
• 9.5 France
  • 9.5.1 Active Clinical Trials
  • 9.5.2 Key Sponsors
  • 9.5.3 Research Infrastructure
  • 9.5.4 Regulatory Environment
  • 9.5.5 Funding Trends
  • 9.5.6 Investigator Activity
  • 9.5.7 Future Growth Opportunities
• 9.6 Italy
  • 9.6.1 Active Clinical Trials
  • 9.6.2 Key Sponsors
  • 9.6.3 Research Infrastructure
  • 9.6.4 Regulatory Environment
  • 9.6.5 Funding Trends
  • 9.6.6 Investigator Activity
  • 9.6.7 Future Growth Opportunities
• 9.7 Spain
  • 9.7.1 Active Clinical Trials
  • 9.7.2 Key Sponsors
  • 9.7.3 Research Infrastructure
  • 9.7.4 Regulatory Environment
  • 9.7.5 Funding Trends
  • 9.7.6 Investigator Activity
  • 9.7.7 Future Growth Opportunities
• 9.8 China
  • 9.8.1 Active Clinical Trials
  • 9.8.2 Key Sponsors
  • 9.8.3 Research Infrastructure
  • 9.8.4 Regulatory Environment
  • 9.8.5 Funding Trends
  • 9.8.6 Investigator Activity
  • 9.8.7 Future Growth Opportunities
• 9.9 Japan
  • 9.9.1 Active Clinical Trials
  • 9.9.2 Key Sponsors
  • 9.9.3 Research Infrastructure
  • 9.9.4 Regulatory Environment
  • 9.9.5 Funding Trends
  • 9.9.6 Investigator Activity
  • 9.9.7 Future Growth Opportunities
• 9.10 India
  • 9.10.1 Active Clinical Trials
  • 9.10.2 Key Sponsors
  • 9.10.3 Research Infrastructure
  • 9.10.4 Regulatory Environment
  • 9.10.5 Funding Trends
  • 9.10.6 Investigator Activity
  • 9.10.7 Future Growth Opportunities

10. Key Drug Profiles

• 10.1 ATH434
  • 10.1.1 Drug Overview
  • 10.1.2 Mechanism of Action
  • 10.1.3 Clinical Development Status
  • 10.1.4 Clinical Trial Results
  • 10.1.5 Safety Profile
  • 10.1.6 Future Development Plans
• 10.2 Verdiperstat
  • 10.2.1 Drug Overview
  • 10.2.2 Mechanism of Action
  • 10.2.3 Clinical Development Status
  • 10.2.4 Clinical Trial Results
  • 10.2.5 Safety Profile
  • 10.2.6 Future Development Plans
• 10.3 Lu AF82422
  • 10.3.1 Drug Overview
  • 10.3.2 Mechanism of Action
  • 10.3.3 Clinical Development Status
  • 10.3.4 Clinical Trial Results
  • 10.3.5 Safety Profile
  • 10.3.6 Future Development Plans
• 10.4 Ampreloxetine
  • 10.4.1 Drug Overview
  • 10.4.2 Mechanism of Action
  • 10.4.3 Clinical Development Status
  • 10.4.4 Clinical Trial Results
  • 10.4.5 Safety Profile
  • 10.4.6 Future Development Plans

11. Company Profiles

• 11.1 Alterity Therapeutics Limited
  • 11.1.1 Overview
  • 11.1.2 Financials
  • 11.1.3 MSA Pipeline Portfolio
  • 11.1.4 Clinical Development Strategy
  • 11.1.5 Key Drug Candidates
  • 11.1.6 Clinical Trial Programs
  • 11.1.7 Strategic Collaborations
  • 11.1.8 Recent Developments
• 11.2 Biohaven Ltd.
  • 11.2.1 Overview
  • 11.2.2 Financials
  • 11.2.3 MSA Pipeline Portfolio
  • 11.2.4 Clinical Development Strategy
  • 11.2.5 Key Drug Candidates
  • 11.2.6 Clinical Trial Programs
  • 11.2.7 Strategic Collaborations
  • 11.2.8 Recent Developments
• 11.3 Lundbeck A/S
  • 11.3.1 Overview
  • 11.3.2 Financials
  • 11.3.3 MSA Pipeline Portfolio
  • 11.3.4 Clinical Development Strategy
  • 11.3.5 Key Drug Candidates
  • 11.3.6 Clinical Trial Programs
  • 11.3.7 Strategic Collaborations
  • 11.3.8 Recent Developments
• 11.4 Neurocrine Biosciences, Inc.
  • 11.4.1 Overview
  • 11.4.2 Financials
  • 11.4.3 MSA Pipeline Portfolio
  • 11.4.4 Clinical Development Strategy
  • 11.4.5 Key Drug Candidates
  • 11.4.6 Clinical Trial Programs
  • 11.4.7 Strategic Collaborations
  • 11.4.8 Recent Developments
• 11.5 AbbVie Inc.
  • 11.5.1 Overview
  • 11.5.2 Financials
  • 11.5.3 MSA Pipeline Portfolio
  • 11.5.4 Clinical Development Strategy
  • 11.5.5 Key Drug Candidates
  • 11.5.6 Clinical Trial Programs
  • 11.5.7 Strategic Collaborations
  • 11.5.8 Recent Developments
• 11.6 UCB S.A.
  • 11.6.1 Overview
  • 11.6.2 Financials
  • 11.6.3 MSA Pipeline Portfolio
  • 11.6.4 Clinical Development Strategy
  • 11.6.5 Key Drug Candidates
  • 11.6.6 Clinical Trial Programs
  • 11.6.7 Strategic Collaborations
  • 11.6.8 Recent Developments
• 11.7 Ionis Pharmaceuticals, Inc.
  • 11.7.1 Overview
  • 11.7.2 Financials
  • 11.7.3 MSA Pipeline Portfolio
  • 11.7.4 Clinical Development Strategy
  • 11.7.5 Key Drug Candidates
  • 11.7.6 Clinical Trial Programs
  • 11.7.7 Strategic Collaborations
  • 11.7.8 Recent Developments
• 11.8 Prothena Corporation plc
  • 11.8.1 Overview
  • 11.8.2 Financials
  • 11.8.3 MSA Pipeline Portfolio
  • 11.8.4 Clinical Development Strategy
  • 11.8.5 Key Drug Candidates
  • 11.8.6 Clinical Trial Programs
  • 11.8.7 Strategic Collaborations
  • 11.8.8 Recent Developments
• 11.9 Takeda Pharmaceutical Company Limited
  • 11.9.1 Overview
  • 11.9.2 Financials
  • 11.9.3 MSA Pipeline Portfolio
  • 11.9.4 Clinical Development Strategy
  • 11.9.5 Key Drug Candidates
  • 11.9.6 Clinical Trial Programs
  • 11.9.7 Strategic Collaborations
  • 11.9.8 Recent Developments
• 11.10 Biogen Inc.
  • 11.10.1 Overview
  • 11.10.2 Financials
  • 11.10.3 MSA Pipeline Portfolio
  • 11.10.4 Clinical Development Strategy
  • 11.10.5 Key Drug Candidates
  • 11.10.6 Clinical Trial Programs
  • 11.10.7 Strategic Collaborations
  • 11.10.8 Recent Developments
• 11.11 Roche Holding AG
  • 11.11.1 Overview
  • 11.11.2 Financials
  • 11.11.3 MSA Pipeline Portfolio
  • 11.11.4 Clinical Development Strategy
  • 11.11.5 Key Drug Candidates
  • 11.11.6 Clinical Trial Programs
  • 11.11.7 Strategic Collaborations
  • 11.11.8 Recent Developments
• 11.12 AstraZeneca PLC
  • 11.12.1 Overview
  • 11.12.2 Financials
  • 11.12.3 MSA Pipeline Portfolio
  • 11.12.4 Clinical Development Strategy
  • 11.12.5 Key Drug Candidates
  • 11.12.6 Clinical Trial Programs
  • 11.12.7 Strategic Collaborations
  • 11.12.8 Recent Developments

12. Partnership, Licensing and M&A Analysis

• 12.1 Strategic Collaborations
• 12.2 Licensing Agreements
• 12.3 Co-Development Partnerships
• 12.4 Research Alliances
• 12.5 Merger and Acquisition Activity
• 12.6 Investment Trends
• 12.7 Future Partnership Opportunities

13. Future Outlook and Opportunity Assessment

• 13.1 Future Pipeline Evolution
• 13.2 Next-Generation Therapeutic Approaches
• 13.3 Disease-Modifying Therapy Outlook
• 13.4 Commercial Opportunity Assessment
• 13.5 Clinical Development Outlook
• 13.6 Key Upcoming Catalysts
• 13.7 Future Market Entry Opportunities

14. Research Methodology

• 14.1 Primary Research
• 14.2 Secondary Research
• 14.3 Pipeline Assessment Methodology
• 14.4 Clinical Trial Assessment Methodology
• 14.5 Data Validation and Triangulation
• 14.6 Assumptions and Limitations

15. Appendix

• 15.1 Abbreviations
• 15.2 Glossary of Terms
• 15.3 References
• 15.4 List of Tables
• 15.5 List of Figures
• 15.6 Clinical Trial Databases Reviewed
• 15.7 Company Information Sourc